D型肝炎の世界市場レポート 2025年

D型肝炎の市場規模は、今後数年間で安定した成長が見込まれます。2029年にはCAGR4.4％で9億米ドルに成長します。予測期間の成長は、新規治療に対する償還政策の拡大、ヘルスケア分野への投資の増加、併用治療の採用拡大、B型肝炎ワクチン接種率の向上、公衆衛生イニシアチブの高まりなどに起因すると考えられます。主な動向としては、分子診断ツールの発展、肝疾患管理における個別化医療へのシフト、新規RNAベース治療の開発、D型肝炎治療における臨床試験の拡大、肝炎管理における遠隔医療の利用拡大などが挙げられます。

B型肝炎の有病率の上昇は、今後数年間のD型肝炎市場の成長を促進すると予想されています。B型肝炎は肝臓を冒し、黄疸、疲労、腹痛などの症状を引き起こすウイルス感染症で、放置すると慢性肝疾患や肝がんにつながる可能性があります。B型肝炎患者の増加は、無防備な性的接触、注射針の共有、出産時の母子感染、特定の地域におけるワクチン接種率の不足などの要因によるものです。D型肝炎は、B型肝炎ウイルスの複製に依存し、その表面抗原を利用して肝細胞に感染するため、両ウイルスへの重複感染が肝疾患の進行に大きく関与しています。例えば、2023年11月、米国保健社会福祉省は、2022年に新たに報告されたB型慢性肝炎症例が前年比で11％増加したと報告しました。その結果、B型肝炎の有病率の増加がD型肝炎市場の拡大に拍車をかけています。

D型肝炎市場の主要企業は、免疫効果を向上させ、ウイルスに対する予防効果を長期間持続させるため、組み換えワクチンなどの革新的製剤の開発に注力しています。組換えワクチンは、ウイルスタンパク質をコードする遺伝子を細菌や酵母などの宿主生物に挿入することで製造され、病気を引き起こすことなく免疫反応を刺激するタンパク質の産生を可能にします。例えば、2022年12月、米国のバイオテクノロジー企業であるVBI Vaccines Inc.は、カナダ保健省から、18歳以上の成人における既知のすべてのB型肝炎亜型に対する積極的予防接種用ワクチンであるPreHevbrio［3抗原B型肝炎ワクチン（遺伝子組換え）］の承認を取得しました。この承認は、D型肝炎の原因であるデルタ菌はB型肝炎感染なしでは存在できないため、D型肝炎の予防にも適用されます。今回の決定は、PROTECTおよびCONSTANTという2つの重要な第3相臨床試験の良好な結果に基づいており、単一抗原のEngerix-Bワクチンと比較して、PreHevbrioの血清防御率が高いことが実証されました。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界D型肝炎PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のD型肝炎市場：成長率分析
• 世界のD型肝炎市場の実績：規模と成長, 2019-2024
• 世界のD型肝炎市場の予測：規模と成長, 2024-2029, 2034F
• 世界D型肝炎総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のD型肝炎市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 急性
• 慢性
• 世界のD型肝炎市場診断別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 血液検査
• エラストグラフィー
• 肝生検
• 血清学的検査
• その他の診断
• 世界のD型肝炎市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界のD型肝炎市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• クリニック
• 病院
• その他のエンドユーザー
• 世界のD型肝炎市場急性のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 自己限定性急性D型肝炎
• 重度の急性D型肝炎
• 世界のD型肝炎市場慢性疾患のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 代償性慢性D型肝炎
• 代償不全慢性D型肝炎

第7章 地域別・国別分析

• 世界のD型肝炎市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のD型肝炎市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• D型肝炎市場：競合情勢
• D型肝炎市場：企業プロファイル
  • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
  • GSK plc Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Gilead Sciences Inc.
• Viatris Inc
• VBI Vaccines Inc
• Alnylam Pharmaceuticals Inc.
• Arrowhead Pharmaceuticals Inc.
• Dynavax Technologies Corporation
• Echosens S.A
• Arbutus Biopharma Corporation
• PROBIOMED SA de CV
• Assembly Biosciences Inc.
• Replicor Inc.
• Eiger BioPharmaceuticals Inc
• Bluejay Therapeutics Inc
• Janssen Pharmaceuticals Inc.
• Transgene SA

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• D型肝炎市場2029：新たな機会を提供する国
• D型肝炎市場2029：新たな機会を提供するセグメント
• D型肝炎市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Hepatitis D, also referred to as hepatitis delta, is a liver infection caused by the hepatitis D virus (HDV). It is regarded as the most severe form of viral hepatitis and occurs exclusively in individuals already infected with the hepatitis B virus (HBV). The hepatitis D virus relies on the hepatitis B virus for replication and survival, making it either a co-infection or a superinfection.

The primary types of hepatitis D are acute and chronic. Acute hepatitis D is a sudden and severe liver infection caused by the hepatitis D virus, often leading to rapid-onset symptoms and potential liver complications. Diagnosis is conducted through various methods, including blood tests, elastography, liver biopsy, serologic testing, and other diagnostic techniques. Medications for hepatitis D are distributed through hospital pharmacies, retail pharmacies, and online pharmacies and are utilized by various end-users, including clinics, hospitals, and other healthcare facilities.

The hepatitis D market research report is one of a series of new reports from The Business Research Company that provides hepatitis D market statistics, including the hepatitis D industry global market size, regional shares, competitors with the hepatitis D market share, detailed hepatitis D market segments, market trends, and opportunities, and any further data you may need to thrive in the hepatitis D industry. This hepatitis D market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The hepatitis D market size has grown steadily in recent years. It will grow from $0.72 billion in 2024 to $0.76 billion in 2025 at a compound annual growth rate (CAGR) of 4.6%. The growth during the historic period can be attributed to limited treatment options, a high prevalence in endemic regions, co-infection with hepatitis B, low awareness and diagnosis rates, and government vaccination programs.

The hepatitis D market size is expected to see steady growth in the next few years. It will grow to $0.90 billion in 2029 at a compound annual growth rate (CAGR) of 4.4%. The growth in the forecast period can be attributed to the expansion of reimbursement policies for novel therapies, rising investment in the healthcare sector, increasing adoption of combination treatments, greater hepatitis B vaccination coverage, and growing public health initiatives. Key trends include advancements in molecular diagnostic tools, a shift toward personalized medicine for liver disease management, the development of novel RNA-based therapies, the expansion of clinical trials for hepatitis D treatments, and the increasing use of telemedicine for hepatitis management.

The rising prevalence of hepatitis B is expected to drive the growth of the hepatitis D market in the coming years. Hepatitis B is a viral infection that affects the liver, causing symptoms such as jaundice, fatigue, and abdominal pain, and can lead to chronic liver disease or liver cancer if left untreated. The increasing number of hepatitis B cases is attributed to factors such as unprotected sexual contact, needle sharing, mother-to-child transmission during childbirth, and insufficient vaccination coverage in certain regions. Hepatitis D depends on the hepatitis B virus for replication, using its surface antigen to infect liver cells, making co-infection with both viruses a significant factor in liver disease progression. For example, in November 2023, the US Department of Health and Human Services reported an 11% rise in newly reported chronic hepatitis B cases in 2022 compared to the previous year. As a result, the growing prevalence of hepatitis B is fueling the expansion of the hepatitis D market.

Leading companies in the hepatitis D market are focusing on developing innovative formulations such as recombinant vaccines to improve immunization efficacy and provide long-lasting protection against the virus. Recombinant vaccines are produced by inserting a gene encoding a viral protein into a host organism, such as bacteria or yeast, allowing the production of the protein to stimulate an immune response without causing the disease. For instance, in December 2022, VBI Vaccines Inc., a US-based biotechnology company, received approval from Health Canada for PreHevbrio [3-antigen Hepatitis B Vaccine (Recombinant)], a vaccine for active immunization against all known subtypes of hepatitis B in adults aged 18 and older. This approval also extends to hepatitis D prevention, as the delta agent responsible for hepatitis D cannot exist without a hepatitis B infection. The decision was based on positive results from two pivotal Phase 3 clinical studies, PROTECT and CONSTANT, which demonstrated higher seroprotection rates with PreHevbrio compared to the single-antigen Engerix-B vaccine.

In October 2023, Gilead Sciences Inc., a US-based biopharmaceutical company, partnered with Assembly Biosciences Inc. to advance the development of next-generation antiviral therapies. This collaboration aims to create innovative treatments for serious viral infections, including hepatitis B, herpesviruses, and hepatitis D. Assembly Biosciences Inc. is a US-based biotechnology company specializing in the development of small-molecule therapeutics targeting serious viral diseases, particularly hepatitis B virus (HBV) and herpes viruses.

Major players in the hepatitis d market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bristol-Myers Squibb Company, Abbott Laboratories, GSK plc, Gilead Sciences Inc., Viatris Inc, VBI Vaccines Inc, Alnylam Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Dynavax Technologies Corporation, Echosens S.A, Arbutus Biopharma Corporation, PROBIOMED SA de CV, Assembly Biosciences Inc., Replicor Inc., Eiger BioPharmaceuticals Inc, Bluejay Therapeutics Inc, Janssen Pharmaceuticals Inc., Transgene SA, Vir Biotechnology Inc, and Biorex Diagnostics Ltd.

North America was the largest region in the hepatitis D market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in hepatitis D report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the hepatitis D market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The hepatitis D market consists of revenues earned by entities by providing services such as clinical and diagnostic services, public health and awareness campaigns, research and development services, or treatment services. The market value includes the value of related goods sold by the service provider or included within the service offering. The hepatitis D market also includes sales of antiviral drugs, interferon therapies, nucleic acid polymers, liver transplant services, and diagnostic tests. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Hepatitis D Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on hepatitis d market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for hepatitis d ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The hepatitis d market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Acute; Chronic
• 2) By Diagnosis: Blood Tests; Elastography; Liver Biopsy; Serologic Testing; Other Diagnosis
• 3) By Distribution Channel: Hospital pharmacies; Retail pharmacies; Online Pharmacies
• 4) By End-Users: Clinic; Hospital; Other End Users
• Subsegments:
• 1) By Acute: Self-limiting Acute Hepatitis D; Severe Acute Hepatitis D
• 2) By Chronic: Compensated Chronic Hepatitis D; Decompensated Chronic Hepatitis D
• Companies Mentioned: F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; Bristol-Myers Squibb Company; Abbott Laboratories; GSK plc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Hepatitis D Market Characteristics

3. Hepatitis D Market Trends And Strategies

4. Hepatitis D Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Hepatitis D Growth Analysis And Strategic Analysis Framework

• 5.1. Global Hepatitis D PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Hepatitis D Market Growth Rate Analysis
• 5.4. Global Hepatitis D Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Hepatitis D Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Hepatitis D Total Addressable Market (TAM)

6. Hepatitis D Market Segmentation

• 6.1. Global Hepatitis D Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Acute
• Chronic
• 6.2. Global Hepatitis D Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Blood Tests
• Elastography
• Liver Biopsy
• Serologic Testing
• Other Diagnosis
• 6.3. Global Hepatitis D Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital pharmacies
• Retail pharmacies
• Online Pharmacies
• 6.4. Global Hepatitis D Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Clinic
• Hospital
• Other End Users
• 6.5. Global Hepatitis D Market, Sub-Segmentation Of Acute, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Self-limiting Acute Hepatitis D
• Severe Acute Hepatitis D
• 6.6. Global Hepatitis D Market, Sub-Segmentation Of Chronic, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Compensated Chronic Hepatitis D
• Decompensated Chronic Hepatitis D

7. Hepatitis D Market Regional And Country Analysis

• 7.1. Global Hepatitis D Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Hepatitis D Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Hepatitis D Market

• 8.1. Asia-Pacific Hepatitis D Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Hepatitis D Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Hepatitis D Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Hepatitis D Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Hepatitis D Market

• 9.1. China Hepatitis D Market Overview
• 9.2. China Hepatitis D Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Hepatitis D Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Hepatitis D Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Hepatitis D Market

• 10.1. India Hepatitis D Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Hepatitis D Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Hepatitis D Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Hepatitis D Market

• 11.1. Japan Hepatitis D Market Overview
• 11.2. Japan Hepatitis D Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Hepatitis D Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Hepatitis D Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Hepatitis D Market

• 12.1. Australia Hepatitis D Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Hepatitis D Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Hepatitis D Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Hepatitis D Market

• 13.1. Indonesia Hepatitis D Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Hepatitis D Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Hepatitis D Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Hepatitis D Market

• 14.1. South Korea Hepatitis D Market Overview
• 14.2. South Korea Hepatitis D Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Hepatitis D Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Hepatitis D Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Hepatitis D Market

• 15.1. Western Europe Hepatitis D Market Overview
• 15.2. Western Europe Hepatitis D Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Hepatitis D Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Hepatitis D Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Hepatitis D Market

• 16.1. UK Hepatitis D Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Hepatitis D Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Hepatitis D Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Hepatitis D Market

• 17.1. Germany Hepatitis D Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Hepatitis D Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Hepatitis D Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Hepatitis D Market

• 18.1. France Hepatitis D Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Hepatitis D Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Hepatitis D Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Hepatitis D Market

• 19.1. Italy Hepatitis D Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Hepatitis D Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Hepatitis D Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Hepatitis D Market

• 20.1. Spain Hepatitis D Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Hepatitis D Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Hepatitis D Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Hepatitis D Market

• 21.1. Eastern Europe Hepatitis D Market Overview
• 21.2. Eastern Europe Hepatitis D Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Hepatitis D Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Hepatitis D Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Hepatitis D Market

• 22.1. Russia Hepatitis D Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Hepatitis D Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Hepatitis D Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Hepatitis D Market

• 23.1. North America Hepatitis D Market Overview
• 23.2. North America Hepatitis D Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Hepatitis D Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Hepatitis D Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Hepatitis D Market

• 24.1. USA Hepatitis D Market Overview
• 24.2. USA Hepatitis D Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Hepatitis D Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Hepatitis D Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Hepatitis D Market

• 25.1. Canada Hepatitis D Market Overview
• 25.2. Canada Hepatitis D Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Hepatitis D Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Hepatitis D Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Hepatitis D Market

• 26.1. South America Hepatitis D Market Overview
• 26.2. South America Hepatitis D Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Hepatitis D Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Hepatitis D Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Hepatitis D Market

• 27.1. Brazil Hepatitis D Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Hepatitis D Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Hepatitis D Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Hepatitis D Market

• 28.1. Middle East Hepatitis D Market Overview
• 28.2. Middle East Hepatitis D Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Hepatitis D Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Hepatitis D Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Hepatitis D Market

• 29.1. Africa Hepatitis D Market Overview
• 29.2. Africa Hepatitis D Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Hepatitis D Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Hepatitis D Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Hepatitis D Market Competitive Landscape And Company Profiles

• 30.1. Hepatitis D Market Competitive Landscape
• 30.2. Hepatitis D Market Company Profiles
  • 30.2.1. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. GSK plc Overview, Products and Services, Strategy and Financial Analysis

31. Hepatitis D Market Other Major And Innovative Companies

• 31.1. Gilead Sciences Inc.
• 31.2. Viatris Inc
• 31.3. VBI Vaccines Inc
• 31.4. Alnylam Pharmaceuticals Inc.
• 31.5. Arrowhead Pharmaceuticals Inc.
• 31.6. Dynavax Technologies Corporation
• 31.7. Echosens S.A
• 31.8. Arbutus Biopharma Corporation
• 31.9. PROBIOMED SA de CV
• 31.10. Assembly Biosciences Inc.
• 31.11. Replicor Inc.
• 31.12. Eiger BioPharmaceuticals Inc
• 31.13. Bluejay Therapeutics Inc
• 31.14. Janssen Pharmaceuticals Inc.
• 31.15. Transgene SA

32. Global Hepatitis D Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Hepatitis D Market

34. Recent Developments In The Hepatitis D Market

35. Hepatitis D Market High Potential Countries, Segments and Strategies

• 35.1 Hepatitis D Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Hepatitis D Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Hepatitis D Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer